The risk of fragility fractures in men with prostate cancer treated with androgen deprivation therapy
Main finding · Fragility fracturesResult — go to the resultHazard ratio 3.61 95% CI 1.57–8.30Authors' conclusion
Current ADT use was associated with a higher risk of fragility fractures than no-ADT use. A higher fracture risk was observed within the first six months of ADT use and persisted for longer durations.
Study context
- Population
- Men with prostate cancer (mean age 70.5 (± 8.3) years)60 with fracture
- Participants
- 471 men
- Exposure
- Current Androgen Deprivation Therapy (ADT) use vs no-ADT use
- Outcome
- Fragility and malignancy-related fractures
Methodological detailscause-specific Cox proportional hazard models, 30-day exposure intervals
- Cause-specific Cox proportional hazard models
- 30-day exposure intervals
Main finding
Fragility fractures
Hazard ratio
3.61
95% CI 1.57–8.30
Current ADT usevs No-ADT use
HR 3.61 (95% CI 1.57–8.30)
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | HR (95% CI) | |
|---|---|---|
| All fracturesCurrent ADT usevs No-ADT use | 5.10 (2.34–11.13) | |
| 0.050.21520Hazard ratio (log scale) |
All fractures
- Increased risk of all fractures with longer duration of ADT use
Original publication
The risk of fragility fractures in men with prostate cancer treated with androgen deprivation therapy. Osteoporos Int. Published 18 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →